2-bromo-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide → 2-(propylamino)-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide
反応式
Br[C:2]1[S:3][C:4]([C:7]([NH:9][C:10]2[S:11][C:12]([C:15](=[O:29])[NH:16][C:17]3[S:18][CH:19]=[C:20]([C:22]4[CH:27]=[CH:26][C:25]([CH3:28])=[CH:24][CH:23]=4)[N:21]=3)=[CH:13][N:14]=2)=[O:8])=[CH:5][N:6]=1>C(N)CC>[CH2:5]([NH:6][C:2]1[S:3][C:4]([C:7]([NH:9][C:10]2[S:11][C:12]([C:15](=[O:29])[NH:16][C:17]3[S:18][CH:19]=[C:20]([C:22]4[CH:27]=[CH:26][C:25]([CH3:28])=[CH:24][CH:23]=4)[N:21]=3)=[CH:13][N:14]=2)=[O:8])=[CH:5][N:6]=1)[CH2:4][CH3:7]参加物
3
実験手順
A solution of 2-bromo-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)thiazol-2-yl)thiazole-5-carboxamide (15 mg, 0.03 mmol) in neat propylamine (0.5 mL) was stirred at reflux for 24 hrs. The solvent was evaporated and the crude product was purified by column chromatography (0%-5% MeOH/AcOEt) yielding 2-(propylamino)-N-(5-(4-p-tolylthiazol-2-ylcarbamoyl)-thiazol-2-yl)thiazole-5-carboxamide (15 mg, 17%).